Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Potentiation of the Therapeutic Effect of Intravesical Bcg Through Synthetic and Biogenic Selenium Nanoparticles in a Nitrosamine-Induced Bladder Cancer Mouse Model Publisher



Ajideh R1 ; Pourmand MR2 ; Faramarzi MA1 ; Sepehrizadeh Z1 ; Pourmand G3 ; Hassanzadeh SM4 ; Mahdavi M5, 6 ; Shahverdi AR1, 5 ; Yazdi MH1, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. BCG Vaccine Department, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
  5. 5. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Source: Advances in Cancer Biology - Metastasis Published:2022


Abstract

Introduction: Intravesical Mycobacterium Bovis bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer has been successfully applied to prevent metastasis and disease progression. However, some studies have reported a percentage of treatment failure and recurrence along with possible side effects. Therefore, this study has evaluated the effect of administration of synthetic (SSeNPs) and biogenic selenium nanoparticles (BSeNPs) as an adjuvant drug in combination with intravesical BCG for the treatment of mice-bearing bladder tumors. Methods: Orthotopic bladder cancer model mice were established by 12 weeks of N-butyl-N-(4-hydroxybutyl) nitrosamine oral gavage. Mice-bearing bladder cancer was treated by sequential intravesical treatments with SSeNPs, BCG, BCG/SSeNPs, and BCG/SSeNPs. After immunotherapy, the status of the immune system was evaluated by quantitatively measuring mRNA expression of cytokines by Real-time qRT-PCR in the spleen samples and measuring cytokines protein level by enzyme-linked immunosorbent assay in the serum samples. As well, in the tumor microenvironment, the mRNA expression level of autophagic molecules (Beclin-1, ATG2B, and ATG5), apoptotic molecule (Caspase-3), iNOS, HMGB1, and PD-L1 were evaluated in all groups. Results: Immunotherapy with BCG/SSeNPs and BCG/BSeNPs elicited a considerable immune response by increasing the expression of IFN-γ, IL-12, and IL-6 and inhibiting the expression of IL-10 and TGF-β cytokines. As well, BCG/SSeNPs and BCG/BSeNPs could increase Caspase-3 expression and decrease autophagic genes as well as PD-L1. Conclusion: Our results showed that synthetic and biogenic SeNPs as an effective adjuvant could enhance intravesical BCG's efficacy and therapeutic effect for bladder cancer treatment with almost the same function. © 2022 The Authors
Other Related Docs
10. Tumor Immunology, Clinical Immunology (2022)